Johannes Hans Berkhof - Epidemiology

Author Information

Johannes Hans Berkhof is affiliated with the Amsterdam UMC Location Vrije Universiteit Amsterdam, specifically within the Epidemiology and Data Science department. He is also a part of the Amsterdam Public Health, Methodology group. His work is based in Amsterdam, the Netherlands.

Research Contributions

Johannes Hans Berkhof has made significant contributions to the field of epidemiology, particularly in the areas of cancer screening and biomarker research. His recent work includes studies on cervical cancer screening, DNA methylation markers for cancer risk prediction, and the clinical performance of high-risk HPV testing. Notably, his research also delves into the heterogeneity in the classification of high-grade cervical intraepithelial neoplasia and the role of cisplatin in treating HPV-positive oropharyngeal cancer. Berkhof's research has substantial implications for improving cancer screening strategies and patient management.

Aliases

J Berkhof, J. Berkhof, Johannes Hans Berkhof, Johannes Berkhof

Publication and Citation Metrics

Metric	Value
Total Citation Count	16585
H-index	68
Total Number of Papers	329

Publications:

The IARC Perspective on Cervical Cancer Screening

DOI: 10.1097/ogx.0000000000001017

Year: 2022

DNA methylation markers for cancer risk prediction of vulvar intraepithelial neoplasia

DOI: 10.1002/ijc.33459

Year: 2021

Biomarker testing in MCI patients—deciding who to test

DOI: 10.1186/s13195-020-00763-7

Year: 2021

Classification of high‐grade cervical intraepithelial neoplasia by p16ink4a, Ki‐67, HPV E4 and FAM19A4/miR124‐2 methylation status demonstrates considerable heterogeneity with potential consequences for management

DOI: 10.1002/ijc.33566

Year: 2021

Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: An observational study.

DOI: 10.1016/j.lanepe.2021.100235

Year: 2021

Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping

DOI: 10.1038/s41416-021-01614-4

Year: 2021

Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV‐positive women: Results from a Dutch primary HPV‐based screening cohort

DOI: 10.1002/ijc.33820

Year: 2021

Comparing the sensitivities of two screening tests in nonblinded randomized paired screen‐positive trials with differential screening uptake

DOI: 10.1002/sim.9215

Year: 2021

The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis.

DOI: 10.1016/j.oraloncology.2021.105454

Year: 2021

A Bayesian accelerated failure time model for interval censored three-state screening outcomes

DOI:

Year: 2021

How is Raw Data Used in Disease Surveillance?

What is Enhancing in Epidemiology?

What is Venipuncture?

How Are Telephone Surveys Conducted?

What is a Study Population?

What is Pre-eclampsia?

Why is Studying Phenomena Important in Epidemiology?

What is Information Technology in Epidemiology?

What are the Advantages of KOH Preparation?

What is Ecological Momentary Assessment (EMA)?

Partnered Content Networks

Relevant Topics